In conclusion, this is the first research to examine the efficacy of inotersen on NIS and NIS-LL scores among subgroups of patients with ATTRv-PN based on key clinical characteristics, such as genetic mutation, FAP stage, pretreatment status, presence of cardiomyopathy, and age of onset. The gene discussed is FAP; the disease is cardiomyopathy.